CAS Key Laboratory of Mental Health,
Institute of Psychology, Chinese Academy of Sciences (CAS)
16 Lincui Road, Chaoyang District, Beijing, 100101,China
Tel: (86-10)64879520
Email: zhangxy@psych.ac.cn
Research Areas
Clinical Psychological Therapy and Counseling
Cognitive Function Research in Mental Disorders
Relationship Between Smoking and Mental Disorders
Free Radical Metabolism in Mental Disorders
Immune Function in Mental Disorders
Genetic Research in Mental Disorders
Neurotrophic Factor Research in Mental Disorders
Neuroelectrophysiological Research in Mental Disorders
Magnetic Resonance Imaging Research in Mental Disorders
Clinical Psychopharmacology Research in Mental Disorders: Clinical Efficacy and Three Major Side Effects of Drugs (Tardive Dyskinesia, Diabetes, and Obesity)
Education
Ph.D. Psychopharmacology, Institute of Mental Health, Peking University School of Medicine,
Beijing, CHINA. Sep 1995-July 1998
M.S. Psychopharmacology, Institute of Mental Health, Peking University School of Medicine,
Beijing, CHINA. Sep 1992-July 1995
M.D. Anhui Medical University, HeFei, Anhui, CHINA. Sep 1984- July 1989
Experience
Work Experience
March 2018- present Professor, Institute of Psychology
Chinese Academy of Sciences, Beijing, China
July 2014- Feb 2018 Associate Professor, Attending Psychiatrist
Department of Psychiatry and Behavioral Sciences,
The University of Texas Health Science Center at Houston, Texas, USA
July 2009- July 2014 Associate Professor, Department of Psychiatry and Behavioral Sciences,
Baylor College of Medicine, Houston, Texas, USA
July 2006-June 2009 Assistant Professor, Department of Psychiatry and Behavioral Sciences,
Baylor College of Medicine
July 2003-June 2006 Associate Research Scientist, Department of Psychiatry,
Yale University School of Medicine, Connecticut, USA
Aug 2000-June 2003 Postdoctoral Fellow, Department of Psychiatry,
Yale University School of Medicine, Connecticut, USA
Aug 1999-July 2000 Postdoctoral Fellow, Center for Molecular and Behavioral Neuroscience
Rutgers University, New Jersey, USA
Aug 1998-July 1999 Research Fellow, Institute of Mental Health,
Peking University School of Medicine, Beijing, China
Aug 1994-July 1998 Attending Psychiatrist, Beijing Hui-Long-Guan Psychiatric Hospital,
Beijing, China
Aug 1989-July 1994 Resident in Psychiatry, Beijing Hui-Long-Guan Psychiatric Hospital,
Beijing, China
Publications
Papers
1. Li X,Liu J, Wei S, Yu C, Wang D, Li Y, Li J, Zhuang W, Luo R, Li Y, Liu Z, Su Y, Liu J, Xu Y, Fan J, Zhu G, Xu W, Tang Y, Yan H, Cho RY, Kosten TR, Zhou D, Zhang X. Cognitive enhancing effect of rTMS combined with tDCS in patients with major depressive disorder: A double-blind, randomized, sham-controlled study. BMC Medicine 2024 (in print) (IF=9.3)
2. Wang DM, Chen DC, Xiu MH, Wang L, Kosten TR, Zhang XY. A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naïve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology 2024 Apr;49(5):893-902(IF=7.6)
3.Qu M, Yang K, Cao Y, Wang X, Tan S, Xiu M, Zhang X. Symptoms of Anxiety and Depression Among Adolescents Before vs During COVID-19-Related School Closures in China. JAMA Network Open 2022; 5(11):e2241752.
4. Zhang XY, Yang M, Du X, Liao W, Chen D, Fan F, Xiu M, Jia Q, Ning Y, Huang X, Wu F, Soares JC, Cao B, Wang L, Chen H. Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Molecular Psychiatry 2020;25(12):3220-3230 (IF=11)
5. Cao B, Cho RY, Chen D, Xiu M, Wang L, Soares JC, Zhang XY. Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity. Molecular Psychiatry 2020; 25(4):906-913 (IF=11)
6. Xiu MH, Li Z, Curbo ME, Wu HE, Chen DC, Chen S, Tong YS, Tan SP, Zhang XY. Interrelationships between BDNF, superoxide dismutase and cognitive impairment in first episode drug-naive patients with schizophrenia. Schizophrenia Bulletin 2020; 46(6):1498-1510
7. Qu M, Wang J, Chen DC, Chen S, Xiu MH, Zhang XY. Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia. Free Radical and Biological Medicine 2020;160:887-893
8. Xia L, Liu L, Hong X, Wang D, Wei G, Wang J, Zhou H, Xu H, Tian Y, Dai Q, Wu HE, Chang C, Wang L, Kosten TR, Zhang XY. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. Neuropsychopharmacology 2020; 45(8):1362-1368
9. Xiu MH, Guan HY, Zhao JM, Wang KQ, Pan YF, Su XR, Wang YH, Guo JM, Jiang L, Liu HY, Sun SG, Wu HR, Liu XW, Yu HJ, Wei BC, Li XP, Trinh T, Tan SP, Zhang XY. Cognitive Enhancing Effect of High-Frequency Neuronavigated rTMS in Chronic Schizophrenia Patients With Predominant Negative Symptoms: A Double-Blind Controlled32-Week Follow-up Study. Schizophrenia Bulletin 2020; 46(5):1219-1230
10. Yang M, Gao S, Zhang X. Cognitive deficits and white matter abnormalities in never- treated first-episode schizophrenia. Translational Psychiatry 2020; 10(1):368.